UCB's Global Corporate Website
Welcome to UCB in the United States

May

06

Evolving Expectations for Arthritis Management

Apr

12

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

Apr

11

Our Leadership and Legacy in Epilepsy and Rare Syndromes

Apr

10

Striving to Make HStory: UCB’s Mission to Raise Awareness for Hidradenitis Suppurativa

Apr

10

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Apr

04

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Mar

19

Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

Mar

09

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Mar

07

Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee